))
The first half of 2024 was strong as M&As and financings dominate
Manage episode 430860080 series 2949057
Content provided by BioWorld Insider Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioWorld Insider Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and potential interest rate cuts. Download transcript
…
continue reading
40 episodes
Share
